Logotipo del repositorio
Logotipo del repositorio
 

Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorChávez-Castillo, Mervin
dc.contributor.authorOrtega, Ángel
dc.contributor.authorCudris-Torres, Lorena
dc.contributor.authorDuran, Pablo
dc.contributor.authorRojas, Milagros
dc.contributor.authorManzano, Alexander
dc.contributor.authorGarrido, Bermary
dc.contributor.authorSalazar, Juan
dc.contributor.authorSilva, Aljadis
dc.contributor.authorRojas-Gomez, Diana Marcela
dc.contributor.authorDe Sanctis, Juan B.
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2021-10-05T14:51:18Z
dc.date.available2021-10-05T14:51:18Z
dc.date.issued2021
dc.description.abstractChronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.spa
dc.format.mimetypepdfspa
dc.identifier.citationChávez-Castillo, M.; Ortega, Á.; Cudris-Torres, L.; Duran, P.; Rojas, M.; Manzano, A.; Garrido, B.; Salazar, J.; Silva, A.; Rojas-Gomez, D.M.; et al. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?. Int. J. Mol. Sci. 2021, 22, 10370. https:// doi.org/10.3390/ijms221910370eng
dc.identifier.doihttps:// doi.org/10.3390/ijms221910370
dc.identifier.issn14220067
dc.identifier.urihttps://hdl.handle.net/20.500.12442/8636
dc.identifier.urlhttps://www.mdpi.com/1422-0067/22/19/10370/htm
dc.language.isoengeng
dc.publisherMDPIeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceInternational Journal of Molecular Scienceseng
dc.sourceVol. 22, No.19 (2021)
dc.subjectChronic paineng
dc.subjectSpecialized pro-resolving lipid mediatorseng
dc.subjectInflammationeng
dc.subjectLong-term potentiationeng
dc.subjectCentral nervous system sensitizationeng
dc.subjectPolyunsaturated fatty acidseng
dc.subjectEicosanoidseng
dc.subjectNociceptioneng
dc.subjectOmega 3 fatty acidseng
dc.subjectPain managementeng
dc.titleSpecialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?eng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesGeurts, J.W.; Willems, P.C.; Lockwood, C.; van Kleef, M.; Kleijnen, J.; Dirksen, C. Patient Expectations for Management of Chronic Non-Cancer Pain: A Systematic Review. Health Expect. 2017, 20, 1201–1217. [CrossRef]eng
dcterms.referencesGBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211–1259. [CrossRef]eng
dcterms.referencesFayaz, A.; Croft, P.; Langford, R.M.; Donaldson, L.J.; Jones, G.T. Prevalence of Chronic Pain in the UK: A Systematic Review and Meta-Analysis of Population Studies. BMJ Open 2016, 6, e010364. [CrossRef] [PubMed]eng
dcterms.referencesKheiry, F.; Rakhshan, M.; Shaygan, M. The prevalence and associated factors of chronic pain in nurses Iran. Latinoam. Hipertens. 2019, 14, 20–25.eng
dcterms.referencesDahlhamer, J.; Lucas, J.; Zelaya, C.; Nahin, R.; Mackey, S.; DeBar, L.; Kerns, R.; Von Korff, M.; Porter, L.; Helmick, C. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults—United States, 2016. MMWR Morb. Mortal. Wkly. Rep. 2018, 67, 1001–1006. [CrossRef] [PubMed]eng
dcterms.referencesDe La Cruz, V.J.A.; Dos Santos, F.; Dyzinger, W.; Herzog, S. Medicina Del Estilo de Vida: Trabajando Juntos Para Revertir La Epidemia de Las Enfermedades Crónicas En Latinoamérica. Cienc. Innovación Salud 2017, 4, 1–7. [CrossRef]spa
dcterms.referencesWorld Health Organization. Opioid Overdose. Available online: https://www.who.int/news-room/fact-sheets/detail/opioidoverdose (accessed on 21 June 2021).eng
dcterms.referencesHern, O.; Saumeth, K.T.; Cabrera, J.L.; Pinz, M. Consumos y Costos de Medicamentos: Herramienta para la Gestión de Suministro del Servicio Farmacéutico. Cienc. Innovación Salud 2015, 3, 45–52. [CrossRef]spa
dcterms.referencesFreire, L.F.L.; Chingo, D.J.A.; Saldarriaga, L.C.Z.; Mera, L.M.I.; Escalante, V.C.G.; Villacres, A.X.Z.; Sanguil, A.T.A.; Bucheli, F.J.J.; Velasco, S.J.S. Alternativas emergentes en la farmacoterapia de la neuralgia del trigémino. AVFT—Arch. Venez. Farmacol. Ter. 2019, 38, 34–39.spa
dcterms.referencesJi, R.-R.; Xu, Z.-Z.; Gao, Y.-J. Emerging Targets in Neuroinflammation-Driven Chronic Pain. Nat. Rev. Drug Discov. 2014, 13, 533–548. [CrossRef]eng
dcterms.referencesValdes, A.M.; Ravipati, S.; Menni, C.; Abhishek, A.; Metrustry, S.; Harris, J.; Nessa, A.; Williams, F.M.K.; Spector, T.D.; Doherty, M.; et al. Association of the Resolvin Precursor 17-HDHA, but Not D- or E- Series Resolvins, with Heat Pain Sensitivity and Osteoarthritis Pain in Humans. Sci. Rep. 2017, 7, 10748. [CrossRef]eng
dcterms.referencesChiang, N.; Serhan, C.N. Structural Elucidation and Physiologic Functions of Specialized Pro-Resolving Mediators and Their Receptors. Mol. Asp. Med. 2017, 58, 114–129. [CrossRef]eng
dcterms.referencesFattori, V.; Zaninelli, T.H.; Rasquel-Oliveira, F.S.; Casagrande, R.; Verri, W.A. Specialized Pro-Resolving Lipid Mediators: A New Class of Non-Immunosuppressive and Non-Opioid Analgesic Drugs. Pharmacol. Res. 2020, 151, 104549. [CrossRef] [PubMed]eng
dcterms.referencesMartini, A.C.; Berta, T.; Forner, S.; Chen, G.; Bento, A.F.; Ji, R.-R.; Rae, G.A. Lipoxin A4 Inhibits Microglial Activation and Reduces Neuroinflammation and Neuropathic Pain after Spinal Cord Hemisection. J. Neuroinflamm. 2016, 13, 75. [CrossRef]eng
dcterms.referencesGoldberg, R.J.; Katz, J. A Meta-Analysis of the Analgesic Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation for Inflammatory Joint Pain. Pain 2007, 129, 210–223. [CrossRef] [PubMed]eng
dcterms.referencesCalder, P.C. Polyunsaturated Fatty Acids and Inflammatory Processes: New Twists in an Old Tale. Biochimie 2009, 91, 791–795. [CrossRef]eng
dcterms.referencesZhang, L.-Y.; Jia, M.-R.; Sun, T. The Roles of Special Proresolving Mediators in Pain Relief. Rev. Neurosci. 2018, 29, 645–660. [CrossRef] [PubMed]eng
dcterms.referencesSchaller, M.S.; Zahner, G.J.; Gasper, W.J.; Harris, W.S.; Conte, M.S.; Hills, N.K.; Grenon, S.M. Relationship between the Omega-3 Index and Specialized pro-Resolving Lipid Mediators in Patients with Peripheral Arterial Disease Taking Fish Oil Supplements. J. Clin. Lipidol. 2017, 11, 1289–1295. [CrossRef]eng
dcterms.referencesLevy, B.D. Resolvins and Protectins: Natural Pharmacophores for Resolution Biology. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82, 327–332. [CrossRef]eng
dcterms.referencesPatrignani, P.; Patrono, C. Cyclooxygenase Inhibitors: From Pharmacology to Clinical Read-Outs. Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2015, 1851, 422–432. [CrossRef]eng
dcterms.referencesSerhan, C.N. Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology. Nature 2014, 510, 92–101. [CrossRef]eng
dcterms.referencesRecchiuti, A.; Serhan, C.N. Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating MiRNA in Novel Resolution Circuits in Inflammation. Front. Immunol. 2012, 3, 298. [CrossRef] [PubMed]eng
dcterms.referencesDalli, J.; Serhan, C.N. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Front. Immunol. 2017, 8, 1400. [CrossRef]eng
dcterms.referencesSerhan, C.N. Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annu. Rev. Immunol. 2007, 25, 101–137. [CrossRef] [PubMed]eng
dcterms.referencesLevy, B.D.; Clish, C.B.; Schmidt, B.; Gronert, K.; Serhan, C.N. Lipid Mediator Class Switching during Acute Inflammation: Signals in Resolution. Nat. Immunol. 2001, 2, 612–619. [CrossRef]eng
dcterms.referencesSerhan, C.N.; Levy, B.D. Resolvins in Inflammation: Emergence of the pro-Resolving Superfamily of Mediators. J. Clin. Investig. 2018, 128, 2657–2669. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N.; Chiang, N.; Dalli, J.; Levy, B.D. Lipid Mediators in the Resolution of Inflammation. Cold Spring Harb. Perspect. Biol. 2014, 7, a016311. [CrossRef]eng
dcterms.referencesFiore, S.; Ryeom, S.W.; Weller, P.F.; Serhan, C.N. Lipoxin Recognition Sites. Specific Binding of Labeled Lipoxin A4 with Human Neutrophils. J. Biol. Chem. 1992, 267, 16168–16176. [CrossRef]eng
dcterms.referencesMinciullo, P.L.; Catalano, A.; Mandraffino, G.; Casciaro, M.; Crucitti, A.; Maltese, G.; Morabito, N.; Lasco, A.; Gangemi, S.; Basile, G. Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity. Arch. Immunol. Ther. Exp. 2016, 64, 111–126. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N.; Krishnamoorthy, S.; Recchiuti, A.; Chiang, N. Novel Anti-Inflammatory–pro-Resolving Mediators and Their Receptors. Curr. Top. Med. Chem. 2011, 11, 629–647. [CrossRef]eng
dcterms.referencesMcMahon, B.; Godson, C. Lipoxins: Endogenous Regulators of Inflammation. Am. J. Physiol. Renal Physiol. 2004, 286, F189–F201. [CrossRef]eng
dcterms.referencesKang, Y.; Taddeo, B.; Varai, G.; Varga, J.; Fiore, S. Mutations of Serine 236–237 and Tyrosine 302 Residues in the Human Lipoxin A4 Receptor Intracellular Domains Result in Sustained Signaling. Biochemistry 2000, 39, 13551–13557. [CrossRef]eng
dcterms.referencesBonnekoh, H.; Scheffel, J.; Wu, J.; Hoffmann, S.; Maurer, M.; Krause, K. Skin and Systemic Inflammation in Schnitzler’s Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Front. Immunol. 2019, 10, 546. [CrossRef]eng
dcterms.referencesBarbu, E.A.; Mendelsohn, L.; Samsel, L.; Thein, S.L. Pro-Inflammatory Cytokines Associate with NETosis during Sickle Cell Vaso-Occlusive Crises. Cytokine 2020, 127, 154933. [CrossRef]eng
dcterms.referencesLi, X.; Yuan, K.; Zhu, Q.; Lu, Q.; Jiang, H.; Zhu, M.; Huang, G.; Xu, A. Andrographolide Ameliorates Rheumatoid Arthritis by Regulating the Apoptosis-NETosis Balance of Neutrophils. Int. J. Mol. Sci. 2019, 20, 5035. [CrossRef] [PubMed]eng
dcterms.referencesHeadland, S.E.; Norling, L.V. The Resolution of Inflammation: Principles and Challenges. Semin. Immunol. 2015, 27, 149–160. [CrossRef] [PubMed]eng
dcterms.referencesRomano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and Aspirin-Triggered Lipoxins in Resolution of Inflammation. Eur. J. Pharmacol. 2015, 760, 49–63. [CrossRef]eng
dcterms.referencesChiang, N.; Bermudez, E.A.; Ridker, P.M.; Hurwitz, S.; Serhan, C.N. Aspirin Triggers Antiinflammatory 15-Epi-Lipoxin A4 and Inhibits Thromboxane in a Randomized Human Trial. Proc. Natl. Acad. Sci. USA 2004, 101, 15178–15183. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N.; Chiang, N.; Van Dyke, T.E. Resolving Inflammation: Dual Anti-Inflammatory and pro-Resolution Lipid Mediators. Nat. Rev. Immunol. 2008, 8, 349–361. [CrossRef] [PubMed]eng
dcterms.referencesO’Meara, S.J.; Rodgers, K.; Godson, C. Lipoxins: Update and Impact of Endogenous pro-Resolution Lipid Mediators. Rev. Physiol. Biochem. Pharmacol. 2008, 160, 47–70. [CrossRef]eng
dcterms.referencesRecchiuti, A.; Mattoscio, D.; Isopi, E. Roles, Actions, and Therapeutic Potential of Specialized Pro-Resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Front. Pharmacol. 2019, 10, 252. [CrossRef]eng
dcterms.referencesRyan, A.; Godson, C. Lipoxins: Regulators of Resolution. Curr. Opin. Pharmacol. 2010, 10, 166–172. [CrossRef]eng
dcterms.referencesMaderna, P.; Cottell, D.C.; Berlasconi, G.; Petasis, N.A.; Brady, H.R.; Godson, C. Lipoxins Induce Actin Reorganization in Monocytes and Macrophages but Not in Neutrophils: Differential Involvement of Rho GTPases. Am. J. Pathol. 2002, 160, 2275–2283. [CrossRef]eng
dcterms.referencesLevy, B.D.; Serhan, C.N. Resolution of Acute Inflammation in the Lung. Annu. Rev. Physiol. 2014, 76, 467–492. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N.; Savill, J. Resolution of Inflammation: The Beginning Programs the End. Nat. Immunol. 2005, 6, 1191–1197. [CrossRef] [PubMed]eng
dcterms.referencesDalli, J.; Serhan, C. Macrophage Proresolving Mediators-the When and Where. Microbiol. Spectr. 2016, 4. [CrossRef] [PubMed]eng
dcterms.referencesAriel, A.; Chiang, N.; Arita, M.; Petasis, N.A.; Serhan, C.N. Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF-Alpha Secretion from Human T Cells. J. Immunol. 2003, 170, 6266–6272. [CrossRef] [PubMed]eng
dcterms.referencesChiurchiù, V.; Leuti, A.; Maccarrone, M. Bioactive Lipids and Chronic Inflammation: Managing the Fire Within. Front. Immunol. 2018, 9, 38. [CrossRef] [PubMed]eng
dcterms.referencesTungen, J.E.; Gerstmann, L.; Vik, A.; De Matteis, R.; Colas, R.A.; Dalli, J.; Chiang, N.; Serhan, C.N.; Kalesse, M.; Hansen, T.V. Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1n-3 DPA. Chemistry 2019, 25, 1476–1480. [CrossRef]eng
dcterms.referencesLatremoliere, A.; Woolf, C.J. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. J. Pain 2009, 10, 895–926. [CrossRef]eng
dcterms.referencesChristensen, J.E.; Andreasen, S.O.; Christensen, J.P.; Thomsen, A.R. CD11b Expression as a Marker to Distinguish between Recently Activated Effector CD8(+) T Cells and Memory Cells. Int. Immunol. 2001, 13, 593–600. [CrossRef]eng
dcterms.referencesChiang, N.; Dalli, J.; Colas, R.A.; Serhan, C.N. Identification of Resolvin D2 Receptor Mediating Resolution of Infections and Organ Protection. J. Exp. Med. 2015, 212, 1203–1217. [CrossRef]eng
dcterms.referencesChiang, N.; de la Rosa, X.; Libreros, S.; Serhan, C.N. Novel Resolvin D2 Receptor Axis in Infectious Inflammation. J. Immunol. 2017, 198, 842–851. [CrossRef]eng
dcterms.referencesDuffney, P.F.; Falsetta, M.L.; Rackow, A.R.; Thatcher, T.H.; Phipps, R.P.; Sime, P.J. Key Roles for Lipid Mediators in the Adaptive Immune Response. J. Clin. Investig. 2018, 128, 2724–2731. [CrossRef]eng
dcterms.referencesKim, N.; Ramon, S.; Thatcher, T.H.; Woeller, C.F.; Sime, P.J.; Phipps, R.P. Specialized Proresolving Mediators (SPMs) Inhibit Human B-Cell IgE Production. Eur. J. Immunol. 2016, 46, 81–91. [CrossRef]eng
dcterms.referencesChen, G.; Zhang, Y.-Q.; Qadri, Y.J.; Serhan, C.N.; Ji, R.-R. Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain. Neuron 2018, 100, 1292–1311. [CrossRef]eng
dcterms.referencesDartt, D.A.; Hodges, R.R.; Serhan, C.N. Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. Adv. Exp. Med. Biol. 2019, 1161, 13–25. [CrossRef]eng
dcterms.referencesSpite, M.; Norling, L.V.; Summers, L.; Yang, R.; Cooper, D.; Petasis, N.A.; Flower, R.J.; Perretti, M.; Serhan, C.N. Resolvin D2 Is a Potent Regulator of Leukocytes and Controls Microbial Sepsis. Nature 2009, 461, 1287–1291. [CrossRef] [PubMed]eng
dcterms.referencesMariani, F.; Roncucci, L. Chemerin/ChemR23 Axis in Inflammation Onset and Resolution. Inflamm. Res. 2015, 64, 85–95. [CrossRef]eng
dcterms.referencesHaworth, O.; Cernadas, M.; Levy, B.D. NK Cells Are Effectors for Resolvin E1 in the Timely Resolution of Allergic Airway Inflammation. J. Immunol. 2011, 186, 6129–6135. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N. Discovery of Specialized Pro-Resolving Mediators Marks the Dawn of Resolution Physiology and Pharmacology. Mol. Asp. Med. 2017, 58, 1–11. [CrossRef] [PubMed]eng
dcterms.referencesSaeki, K.; Yokomizo, T. Identification, Signaling, and Functions of LTB4 Receptors. Semin. Immunol. 2017, 33, 30–36. [CrossRef] [PubMed]eng
dcterms.referencesWu, C.; Sun, A.; Zou, Y.; Ge, J. “Pro-Resolution” and Anti-Inflammation, a Role of RvE1 in Anti-Atherosclerosis and Plaque Stabilization. Med. Hypotheses 2008, 71, 252–255. [CrossRef]eng
dcterms.referencesBuckley, C.D.; Gilroy, D.W.; Serhan, C.N. Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity 2014, 40, 315–327. [CrossRef]eng
dcterms.referencesCorrea, M.D.; López, M.R. Activación alternativa del macrófago: La diversidad en las respuestas de una célula de la inmunidad innata ante la complejidad de los eventos de su ambiente. Inmunologia 2007, 26, 73–86. [CrossRef]spa
dcterms.referencesSerhan, C.N.; Dalli, J.; Colas, R.A.; Winkler, J.W.; Chiang, N. Protectins and Maresins: New pro-Resolving Families of Mediators in Acute Inflammation and Resolution Bioactive Metabolome. Biochim. Biophys. Acta 2015, 1851, 397–413. [CrossRef]eng
dcterms.referencesTang, S.; Wan, M.; Huang, W.; Stanton, R.C.; Xu, Y. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. Mediat. Inflamm. 2018, 2018, 2380319. [CrossRef]eng
dcterms.referencesHwang, S.-M.; Chung, G.; Kim, Y.H.; Park, C.-K. The Role of Maresins in Inflammatory Pain: Function of Macrophages in Wound Regeneration. Int. J. Mol. Sci. 2019, 20, 5849. [CrossRef] [PubMed]eng
dcterms.referencesHäcker, H.; Karin, M. Regulation and Function of IKK and IKK-Related Kinases. Sci. STKE 2006, 2006, re13. [CrossRef]eng
dcterms.referencesBitto, A.; Minutoli, L.; David, A.; Irrera, N.; Rinaldi, M.; Venuti, F.S.; Squadrito, F.; Altavilla, D. Flavocoxid, a Dual Inhibitor of COX-2 and 5-LOX of Natural Origin, Attenuates the Inflammatory Response and Protects Mice from Sepsis. Crit. Care 2012, 16, R32. [CrossRef]eng
dcterms.referencesKohli, P.; Levy, B.D. Resolvins and Protectins: Mediating Solutions to Inflammation. Br. J. Pharmacol. 2009, 158, 960–971. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N. Novel Chemical Mediators in the Resolution of Inflammation: Resolvins and Protectins. Anesthesiol. Clin. 2006, 24, 341–364. [CrossRef] [PubMed]eng
dcterms.referencesKytikova, O.; Novgorodtseva, T.; Denisenko, Y.; Antonyuk, M.; Gvozdenko, T. Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma. Medicina 2019, 55, 284. [CrossRef] [PubMed]eng
dcterms.referencesBang, S.; Xie, Y.-K.; Zhang, Z.-J.; Wang, Z.; Xu, Z.-Z.; Ji, R.-R. GPR37 Regulates Macrophage Phagocytosis and Resolution of Inflammatory Pain. J. Clin. Investig. 2018, 128, 3568–3582. [CrossRef]eng
dcterms.referencesFreire, M.O.; Van Dyke, T.E. Natural Resolution of Inflammation. Periodontology 2000 2013, 63, 149–164. [CrossRef]eng
dcterms.referencesTotsch, S.K.; Sorge, R.E. Immune System Involvement in Specific Pain Conditions. Mol. Pain 2017, 13, 1744806917724559. [CrossRef]eng
dcterms.referencesChavan, S.S.; Pavlov, V.A.; Tracey, K.J. Mechanisms and Therapeutic Relevance of Neuro-Immune Communication. Immunity 2017, 46, 927–942. [CrossRef] [PubMed]eng
dcterms.referencesCury, Y.; Picolo, G.; Gutierrez, V.P.; Ferreira, S.H. Pain and Analgesia: The Dual Effect of Nitric Oxide in the Nociceptive System. Nitric Oxide 2011, 25, 243–254. [CrossRef]eng
dcterms.referencesXu, Z.-Z.; Zhang, L.; Liu, T.; Park, J.Y.; Berta, T.; Yang, R.; Serhan, C.N.; Ji, R.-R. Resolvins RvE1 and RvD1 Attenuate Inflammatory Pain via Central and Peripheral Actions. Nat. Med. 2010, 16, 592–597. [CrossRef] [PubMed]eng
dcterms.referencesHerová, M.; Schmid, M.; Gemperle, C.; Hersberger, M. ChemR23, the Receptor for Chemerin and Resolvin E1, Is Expressed and Functional on M1 but Not on M2 Macrophages. J. Immunol. 2015, 194, 2330–2337. [CrossRef] [PubMed]eng
dcterms.referencesScholz, J.; Woolf, C.J. The Neuropathic Pain Triad: Neurons, Immune Cells and Glia. Nat. Neurosci. 2007, 10, 1361–1368. [CrossRef]eng
dcterms.referencesBingham, B.; Ajit, S.K.; Blake, D.R.; Samad, T.A. The Molecular Basis of Pain and Its Clinical Implications in Rheumatology. Nat. Clin. Pract. Rheumatol. 2009, 5, 28–37. [CrossRef]eng
dcterms.referencesJara-Oseguera, A.; Simon, S.A.; Rosenbaum, T. TRPV1: On the Road to Pain Relief. Curr. Mol. Pharmacol. 2008, 1, 255–269. [CrossRef]eng
dcterms.referencesCampbell, J.N.; Raja, S.N.; Meyer, R.A.; Mackinnon, S.E. Myelinated Afferents Signal the Hyperalgesia Associated with Nerve Injury. Pain 1988, 32, 89–94. [CrossRef]eng
dcterms.referencesSchmidtko, A. Nitric Oxide-Mediated Pain Processing in the Spinal Cord. Handb. Exp. Pharmacol. 2015, 227, 103–117. [CrossRef]eng
dcterms.referencesLim, J.Y.; Park, C.-K.; Hwang, S.W. Biological Roles of Resolvins and Related Substances in the Resolution of Pain. Biomed. Res. Int. 2015, 2015, 830930. [CrossRef]eng
dcterms.referencesSerhan, C.N.; Chiang, N.; Dalli, J. New Pro-Resolving n-3 Mediators Bridge Resolution of Infectious Inflammation to Tissue Regeneration. Mol. Asp. Med. 2018, 64, 1–17. [CrossRef] [PubMed]eng
dcterms.referencesSchwanke, R.C.; Marcon, R.; Bento, A.F.; Calixto, J.B. EPA- and DHA-Derived Resolvins’ Actions in Inflammatory Bowel Disease. Eur. J. Pharmacol. 2016, 785, 156–164. [CrossRef]eng
dcterms.referencesSerhan, C.N.; Dalli, J.; Karamnov, S.; Choi, A.; Park, C.-K.; Xu, Z.-Z.; Ji, R.-R.; Zhu, M.; Petasis, N.A. Macrophage Proresolving Mediator Maresin 1 Stimulates Tissue Regeneration and Controls Pain. FASEB J. 2012, 26, 1755–1765. [CrossRef]eng
dcterms.referencesLiao, H.-Y.; Hsieh, C.-L.; Huang, C.-P.; Lin, Y.-W. Electroacupuncture Attenuates CFA-Induced Inflammatory Pain by Suppressing Nav1.8 through S100B, TRPV1, Opioid, and Adenosine Pathways in Mice. Sci. Rep. 2017, 7, 42531. [CrossRef] [PubMed]eng
dcterms.references
dcterms.referencesYu, Y.-Q.; Zhao, F.; Guan, S.-M.; Chen, J. Antisense-Mediated Knockdown of Na(V)1.8, but Not Na(V)1.9, Generates Inhibitory Effects on Complete Freund’s Adjuvant-Induced Inflammatory Pain in Rat. PLoS ONE 2011, 6, e19865. [CrossRef]eng
dcterms.referencesPark, C.-K. Maresin 1 Inhibits TRPV1 in Temporomandibular Joint-Related Trigeminal Nociceptive Neurons and TMJ Inflammation-Induced Synaptic Plasticity in the Trigeminal Nucleus. Mediat. Inflamm. 2015, 2015, 275126. [CrossRef]eng
dcterms.referencesPark, C.-K.; Lü, N.; Xu, Z.-Z.; Liu, T.; Serhan, C.N.; Ji, R.-R. Resolving TRPV1- and TNF-α-Mediated Spinal Cord Synaptic Plasticity and Inflammatory Pain with Neuroprotectin D1. J. Neurosci. 2011, 31, 15072–15085. [CrossRef]eng
dcterms.referencesPark, C.-K.; Xu, Z.-Z.; Liu, T.; Lü, N.; Serhan, C.N.; Ji, R.-R. Resolvin D2 Is a Potent Endogenous Inhibitor for Transient Receptor Potential Subtype V1/A1, Inflammatory Pain, and Spinal Cord Synaptic Plasticity in Mice: Distinct Roles of Resolvin D1, D2, and E1. J. Neurosci. 2011, 31, 18433–18438. [CrossRef] [PubMed]eng
dcterms.referencesHuang, J.; Burston, J.J.; Li, L.; Ashraf, S.; Mapp, P.I.; Bennett, A.J.; Ravipati, S.; Pousinis, P.; Barrett, D.A.; Scammell, B.E.; et al. Targeting the D Series Resolvin Receptor System for the Treatment of Osteoarthritis Pain. Arthritis Rheumatol. 2017, 69, 996–1008. [CrossRef]eng
dcterms.referencesBang, S.; Yoo, S.; Yang, T.J.; Cho, H.; Kim, Y.G.; Hwang, S.W. Resolvin D1 Attenuates Activation of Sensory Transient Receptor Potential Channels Leading to Multiple Anti-Nociception. Br. J. Pharmacol. 2010, 161, 707–720. [CrossRef] [PubMed]eng
dcterms.referencesMacpherson, L.J.; Xiao, B.; Kwan, K.Y.; Petrus, M.J.; Dubin, A.E.; Hwang, S.; Cravatt, B.; Corey, D.P.; Patapoutian, A. An Ion Channel Essential for Sensing Chemical Damage. J. Neurosci. 2007, 27, 11412–11415. [CrossRef]eng
dcterms.referencesSommer, C.; Birklein, F. Fighting off Pain with Resolvins. Nat. Med. 2010, 16, 518–520. [CrossRef]eng
dcterms.referencesArita, M.; Bianchini, F.; Aliberti, J.; Sher, A.; Chiang, N.; Hong, S.; Yang, R.; Petasis, N.A.; Serhan, C.N. Stereochemical Assignment, Antiinflammatory Properties, and Receptor for the Omega-3 Lipid Mediator Resolvin E1. J. Exp. Med. 2005, 201, 713–722. [CrossRef] [PubMed]eng
dcterms.referencesMeesawatsom, P.; Burston, J.; Hathway, G.; Bennett, A.; Chapman, V. Inhibitory Effects of Aspirin-Triggered Resolvin D1 on Spinal Nociceptive Processing in Rat Pain Models. J. Neuroinflamm. 2016, 13, 233. [CrossRef]eng
dcterms.referencesWoolf, C.J.; Salter, M.W. Neuronal Plasticity: Increasing the Gain in Pain. Science 2000, 288, 1765–1768. [CrossRef]eng
dcterms.references. Liu, X.J.; Gingrich, J.R.; Vargas-Caballero, M.; Dong, Y.N.; Sengar, A.; Beggs, S.; Wang, S.-H.; Ding, H.K.; Frankland, P.W.; Salter, M.W. Treatment of Inflammatory and Neuropathic Pain by Uncoupling Src from the NMDA Receptor Complex. Nat. Med. 2008, 14, 1325–1332. [CrossRef]eng
dcterms.referencesRen, K.; Hylden, J.L.K.; Williams, G.M.; Ruda, M.A.; Dubner, R. The Effects of a Non-Competitive NMDA Receptor Antagonist, MK-801, on Behavioral Hyperalgesia and Dorsal Horn Neuronal Activity in Rats with Unilateral Inflammation. Pain 1992, 50, 331–344. [CrossRef]eng
dcterms.referencesQuan-Xin, F.; Fan, F.; Xiang-Ying, F.; Shu-Jun, L.; Shi-Qi, W.; Zhao-Xu, L.; Xu-Jie, Z.; Qing-Chuan, Z.; Wei, W. Resolvin D1 Reverses Chronic Pancreatitis-Induced Mechanical Allodynia, Phosphorylation of NMDA Receptors, and Cytokines Expression in the Thoracic Spinal Dorsal Horn. BMC Gastroenterol. 2012, 12, 148. [CrossRef]eng
dcterms.referencesOehler, B.; Mohammadi, M.; Perpina Viciano, C.; Hackel, D.; Hoffmann, C.; Brack, A.; Rittner, H.L. Peripheral Interaction of Resolvin D1 and E1 with Opioid Receptor Antagonists for Antinociception in Inflammatory Pain in Rats. Front. Mol. Neurosci. 2017, 10, 242. [CrossRef] [PubMed]eng
dcterms.referencesYaksh, T.L. Substance P Release from Knee Joint Afferent Terminals: Modulation by Opioids. Brain Res. 1988, 458, 319–324. [CrossRef]eng
dcterms.referencesBeaudry, H.; Dubois, D.; Gendron, L. Activation of Spinal Mu- and Delta-Opioid Receptors Potently Inhibits Substance P Release Induced by Peripheral Noxious Stimuli. J. Neurosci. 2011, 31, 13068–13077. [CrossRef] [PubMed]eng
dcterms.referencesKhasabova, I.A.; Harding-Rose, C.; Simone, D.A.; Seybold, V.S. Differential Effects of CB1 and Opioid Agonists on Two Populations of Adult Rat Dorsal Root Ganglion Neurons. J. Neurosci. 2004, 24, 1744–1753. [CrossRef]eng
dcterms.referencesJin, Y.H.; Nishioka, H.; Wakabayashi, K.; Fujita, T.; Yonehara, N. Effect of Morphine on the Release of Excitatory Amino Acids in the Rat Hind Instep: Pain Is Modulated by the Interaction between the Peripheral Opioid and Glutamate Systems. Neuroscience 2006, 138, 1329–1339. [CrossRef]eng
dcterms.referencesCelik, M.Ö.; Labuz, D.; Henning, K.; Busch-Dienstfertig, M.; Gaveriaux-Ruff, C.; Kieffer, B.L.; Zimmer, A.; Machelska, H. Leukocyte Opioid Receptors Mediate Analgesia via Ca(2+)-Regulated Release of Opioid Peptides. Brain Behav. Immun. 2016, 57, 227–242. [CrossRef]eng
dcterms.referencesChuang, T.K.; Killam, K.F.; Chuang, L.F.; Kung, H.F.; Sheng, W.S.; Chao, C.C.; Yu, L.; Chuang, R.Y. Mu Opioid Receptor Gene Expression in Immune Cells. Biochem. Biophys. Res. Commun. 1995, 216, 922–930. [CrossRef] [PubMed]eng
dcterms.referencesToskulkao, T.; Pornchai, R.; Akkarapatumwong, V.; Vatanatunyakum, S.; Govitrapong, P. Alteration of Lymphocyte Opioid Receptors in Methadone Maintenance Subjects. Neurochem. Int. 2010, 56, 285–290. [CrossRef]eng
dcterms.referencesMachelska, H.; Celik, M.Ö. Opioid Receptors in Immune and Glial Cells-Implications for Pain Control. Front. Immunol. 2020, 11, 300. [CrossRef] [PubMed]eng
dcterms.referencesLuo, X.; Gu, Y.; Tao, X.; Serhan, C.N.; Ji, R.-R. Resolvin D5 Inhibits Neuropathic and Inflammatory Pain in Male but Not Female Mice: Distinct Actions of D-Series Resolvins in Chemotherapy-Induced Peripheral Neuropathy. Front. Pharmacol. 2019, 10, 745. [CrossRef]eng
dcterms.referencesKrishnamoorthy, S.; Recchiuti, A.; Chiang, N.; Yacoubian, S.; Lee, C.-H.; Yang, R.; Petasis, N.A.; Serhan, C.N. Resolvin D1 Binds Human Phagocytes with Evidence for Proresolving Receptors. Proc. Natl. Acad. Sci. USA 2010, 107, 1660–1665. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N.; Hong, S.; Gronert, K.; Colgan, S.P.; Devchand, P.R.; Mirick, G.; Moussignac, R.-L. Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment That Counter Proinflammation Signals. J. Exp. Med. 2002, 196, 1025–1037. [CrossRef] [PubMed]eng
dcterms.referencesQu, L.; Caterina, M.J. Accelerating the Reversal of Inflammatory Pain with NPD1 and Its Receptor GPR37. J. Clin. Investig. 2018, 128, 3246–3249. [CrossRef]eng
dcterms.referencesChen, O.; Donnelly, C.R.; Ji, R.-R. Regulation of Pain by Neuro-Immune Interactions between Macrophages and Nociceptor Sensory Neurons. Curr. Opin. Neurobiol. 2020, 62, 17–25. [CrossRef] [PubMed]eng
dcterms.referencesPannell, M.; Labuz, D.; Celik, M.Ö.; Keye, J.; Batra, A.; Siegmund, B.; Machelska, H. Adoptive Transfer of M2 Macrophages Reduces Neuropathic Pain via Opioid Peptides. J. Neuroinflamm. 2016, 13, 262. [CrossRef]eng
dcterms.referencesWang, J.C.-F.; Strichartz, G.R. Prevention of Chronic Post-Thoracotomy Pain in Rats by Intrathecal Resolvin D1 and D2: Effectiveness of Perioperative and Delayed Drug Delivery. J. Pain 2017, 18, 535–545. [CrossRef] [PubMed]eng
dcterms.referencesPamplona, F.A.; Ferreira, J.; de Lima, O.M.; Duarte, F.S.; Bento, A.F.; Forner, S.; Villarinho, J.G.; Bellocchio, L.; Wotjak, C.T.; Lerner, R.; et al. Anti-Inflammatory Lipoxin A4 Is an Endogenous Allosteric Enhancer of CB1 Cannabinoid Receptor. Proc. Natl. Acad. Sci. USA 2012, 109, 21134–21139. [CrossRef] [PubMed]eng
dcterms.referencesZhang, H.; He, S.; Hu, Y.; Zheng, H. Antagonism of Cannabinoid Receptor 1 Attenuates the Anti-Inflammatory Effects of Electroacupuncture in a Rodent Model of Migraine. Acupunct. Med. 2016, 34, 463–470. [CrossRef]eng
dcterms.referencesXu, Z.-Z.; Berta, T.; Ji, R.-R. Resolvin E1 Inhibits Neuropathic Pain and Spinal Cord Microglial Activation Following Peripheral Nerve Injury. J. Neuroimmune Pharmacol. 2013, 8, 37–41. [CrossRef] [PubMed]eng
dcterms.referencesHernangómez, M.; Klusáková, I.; Joukal, M.; Hradilová-Svíženská, I.; Guaza, C.; Dubový, P. CD200R1 Agonist Attenuates Glial Activation, Inflammatory Reactions, and Hypersensitivity Immediately after Its Intrathecal Application in a Rat Neuropathic Pain Model. J. Neuroinflamm. 2016, 13, 43. [CrossRef] [PubMed]eng
dcterms.referencesGao, Y.-J.; Ji, R.-R. Activation of JNK Pathway in Persistent Pain. Neurosci. Lett. 2008, 437, 180–183. [CrossRef]eng
dcterms.referencesTsuda, M.; Inoue, K.; Salter, M.W. Neuropathic Pain and Spinal Microglia: A Big Problem from Molecules in “Small” Glia. Trends Neurosci. 2005, 28, 101–107. [CrossRef]eng
dcterms.referencesSvensson, C.I.; Zattoni, M.; Serhan, C.N. Lipoxins and Aspirin-Triggered Lipoxin Inhibit Inflammatory Pain Processing. J. Exp. Med. 2007, 204, 245–252. [CrossRef]eng
dcterms.referencesMiao, G.-S.; Liu, Z.-H.; Wei, S.-X.; Luo, J.-G.; Fu, Z.-J.; Sun, T. Lipoxin A4 Attenuates Radicular Pain Possibly by Inhibiting Spinal ERK, JNK and NF-KB/P65 and Cytokine Signals, but Not P38, in a Rat Model of Non-Compressive Lumbar Disc Herniation. Neuroscience 2015, 300, 10–18. [CrossRef]eng
dcterms.referencesLiu, J.; Peng, L.; Li, J. The Lipoxin A4 Receptor Agonist BML-111 Alleviates Inflammatory Injury and Oxidative Stress in Spinal Cord Injury. Med. Sci. Monit. 2020, 26, e919883. [CrossRef] [PubMed]eng
dcterms.referencesJi, R.-R.; Suter, M.R. P38 MAPK, Microglial Signaling, and Neuropathic Pain. Mol. Pain 2007, 3, 33. [CrossRef] [PubMed]eng
dcterms.referencesDiamond, P.; Doran, P.; Brady, H.R.; McGinty, A. Suppressors of Cytokine Signalling (SOCS): Putative Modulators of Cytokine Bioactivity in Health and Disease. J. Nephrol. 2000, 13, 9–14eng
dcterms.referencesHu, S.; Mao-Ying, Q.-L.; Wang, J.; Wang, Z.-F.; Mi, W.-L.; Wang, X.-W.; Jiang, J.-W.; Huang, Y.-L.; Wu, G.-C.; Wang, Y.-Q. Lipoxins and Aspirin-Triggered Lipoxin Alleviate Bone Cancer Pain in Association with Suppressing Expression of Spinal Proinflammatory Cytokines. J. Neuroinflamm. 2012, 9, 278. [CrossRef]eng
dcterms.referencesZhang, L.-Y.; Liu, Z.-H.; Zhu, Q.; Wen, S.; Yang, C.-X.; Fu, Z.-J.; Sun, T. Resolvin D2 Relieving Radicular Pain Is Associated with Regulation of Inflammatory Mediators, Akt/GSK-3β Signal Pathway and GPR18. Neurochem. Res. 2018, 43, 2384–2392. [CrossRef] [PubMed]eng
dcterms.referencesXu, Z.-Z.; Liu, X.-J.; Berta, T.; Park, C.-K.; Lü, N.; Serhan, C.N.; Ji, R.-R. Neuroprotectin/Protectin D1 Protects against Neuropathic Pain in Mice after Nerve Trauma. Ann. Neurol. 2013, 74, 490–495. [CrossRef]eng
dcterms.referencesGao, J.; Tang, C.; Tai, L.W.; Ouyang, Y.; Li, N.; Hu, Z.; Chen, X. Pro-Resolving Mediator Maresin 1 Ameliorates Pain Hypersensitivity in a Rat Spinal Nerve Ligation Model of Neuropathic Pain. J. Pain Res. 2018, 11, 1511–1519. [CrossRef]eng
dcterms.referencesFukumoto, M.; Takeuchi, T.; Koubayashi, E.; Harada, S.; Ota, K.; Kojima, Y.; Higuchi, K. Induction of Brain-Derived Neurotrophic Factor in Enteric Glial Cells Stimulated by Interleukin-1β via a c-Jun N-Terminal Kinase Pathway. J. Clin. Biochem. Nutr. 2020, 66, 103–109. [CrossRef]eng
dcterms.referencesYu, Y.-B.; Zuo, X.-L.; Zhao, Q.-J.; Chen, F.-X.; Yang, J.; Dong, Y.-Y.; Wang, P.; Li, Y.-Q. Brain-Derived Neurotrophic Factor Contributes to Abdominal Pain in Irritable Bowel Syndrome. Gut 2012, 61, 685–694. [CrossRef]eng
dcterms.referencesReischer, G.; Heinke, B.; Sandkühler, J. Interferon-γ Facilitates the Synaptic Transmission between Primary Afferent C-Fibres and Lamina I Neurons in the Rat Spinal Dorsal Horn via Microglia Activation. Mol. Pain 2020, 16, 1744806920917249. [CrossRef] [PubMed]eng
dcterms.referencesCoull, J.A.M.; Beggs, S.; Boudreau, D.; Boivin, D.; Tsuda, M.; Inoue, K.; Gravel, C.; Salter, M.W.; De Koninck, Y. BDNF from Microglia Causes the Shift in Neuronal Anion Gradient Underlying Neuropathic Pain. Nature 2005, 438, 1017–1021. [CrossRef] [PubMed]eng
dcterms.referencesKim, D.; Kim, M.A.; Cho, I.-H.; Kim, M.S.; Lee, S.; Jo, E.-K.; Choi, S.-Y.; Park, K.; Kim, J.S.; Akira, S.; et al. A Critical Role of Toll-like Receptor 2 in Nerve Injury-Induced Spinal Cord Glial Cell Activation and Pain Hypersensitivity. J. Biol. Chem. 2007, 282, 14975–14983. [CrossRef]eng
dcterms.referencesZhuang, Z.-Y.; Kawasaki, Y.; Tan, P.-H.; Wen, Y.-R.; Huang, J.; Ji, R.-R. Role of the CX3CR1/P38 MAPK Pathway in Spinal Microglia for the Development of Neuropathic Pain Following Nerve Injury-Induced Cleavage of Fractalkine. Brain Behav. Immun. 2007, 21, 642–651. [CrossRef]eng
dcterms.referencesWu, L.; Liu, Z.J.; Miao, S.; Zou, L.B.; Cai, L.; Wu, P.; Ye, D.Y.; Wu, Q.; Li, H.H. Lipoxin A4 Ameliorates Cerebral Ischaemia/Reperfusion Injury through Upregulation of Nuclear Factor Erythroid 2-Related Factor 2. Neurol. Res. 2013, 35, 968–975. [CrossRef]eng
dcterms.referencesWu, Y.; Zhai, H.; Wang, Y.; Li, L.; Wu, J.; Wang, F.; Sun, S.; Yao, S.; Shang, Y. Aspirin-Triggered Lipoxin A4 Attenuates Lipopolysaccharide-Induced Intracellular ROS in BV2 Microglia Cells by Inhibiting the Function of NADPH Oxidase. Neurochem. Res. 2012, 37, 1690–1696. [CrossRef] [PubMed]eng
dcterms.referencesArita, M.; Ohira, T.; Sun, Y.-P.; Elangovan, S.; Chiang, N.; Serhan, C.N. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation. J. Immunol. 2007, 178, 3912–3917. [CrossRef]eng
dcterms.referencesLiu, Z.-Q.; Zhang, H.-B.; Wang, J.; Xia, L.-J.; Zhang, W. Lipoxin A4 Ameliorates Ischemia/Reperfusion Induced Spinal Cord Injury in Rabbit Model. Int. J. Clin. Exp. Med. 2015, 8, 12826–12833eng
dcterms.referencesLeuti, A.; Maccarrone, M.; Chiurchiù, V. Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress. Oxid. Med. Cell. Longev. 2019, 2019, 8107265. [CrossRef]eng
dcterms.referencesTsujino, H.; Kondo, E.; Fukuoka, T.; Dai, Y.; Tokunaga, A.; Miki, K.; Yonenobu, K.; Ochi, T.; Noguchi, K. Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury. Mol. Cell. Neurosci. 2000, 15, 170–182. [CrossRef]eng
dcterms.referencesOhuchi, K.; Ono, Y.; Joho, M.; Tsuruma, K.; Ogami, S.; Yamane, S.; Funato, M.; Kaneko, H.; Nakamura, S.; Hara, H.; et al. A Docosahexaenoic Acid-Derived Pro-Resolving Agent, Maresin 1, Protects Motor Neuron Cells Death. Neurochem. Res. 2018, 43, 1413–1423. [CrossRef] [PubMed]eng
dcterms.referencesSerhan, C.N.; Chiang, N.; Dalli, J. The Resolution Code of Acute Inflammation: Novel pro-Resolving Lipid Mediators in Resolution. Semin. Immunol. 2015, 27, 200–215. [CrossRef] [PubMed]eng
dcterms.referencesParagomi, P.; Rahimian, R.; Kazemi, M.H.; Gharedaghi, M.H.; Khalifeh-Soltani, A.; Azary, S.; Javidan, A.N.; Moradi, K.; Sakuma, S.; Dehpour, A.R. Antinociceptive and Antidiarrheal Effects of Pioglitazone in a Rat Model of Diarrhoea-Predominant Irritable Bowel Syndrome: Role of Nitric Oxide. Clin. Exp. Pharmacol. Physiol. 2014, 41, 118–126. [CrossRef] [PubMed]eng
dcterms.referencesPiovezan, A.P.; Batisti, A.P.; Benevides, M.L.A.C.S.; Turnes, B.L.; Martins, D.F.; Kanis, L.; Duarte, E.C.W.; Cavalheiro, A.J.; Bueno, P.C.P.; Seed, M.P.; et al. Hydroalcoholic Crude Extract of Casearia Sylvestris Sw. Reduces Chronic Post-Ischemic Pain by Activation of pro-Resolving Pathways. J. Ethnopharmacol. 2017, 204, 179–188. [CrossRef] [PubMed]eng
dcterms.referencesAbdelmoaty, S.; Wigerblad, G.; Bas, D.B.; Codeluppi, S.; Fernandez-Zafra, T.; El-Awady, E.-S.; Moustafa, Y.; Abdelhamid, A.E.S.; Brodin, E.; Svensson, C.I. Spinal Actions of Lipoxin A4 and 17(R)-Resolvin D1 Attenuate Inflammation-Induced Mechanical Hypersensitivity and Spinal TNF Release. PLoS ONE 2013, 8, e75543. [CrossRef]eng
dcterms.referencesLu, T.; Wu, X.; Wei, N.; Liu, X.; Zhou, Y.; Shang, C.; Duan, Y.; Dong, Y. Lipoxin A4 Protects against Spinal Cord Injury via Regulating Akt/Nuclear Factor (Erythroid-Derived 2)-like 2/Heme Oxygenase-1 Signaling. Biomed. Pharmacother. 2018, 97, 905–910. [CrossRef] [PubMed]eng
dcterms.referencesWang, Z.F.; Li, Q.; Liu, S.B.; Mi, W.-L.; Hu, S.; Zhao, J.; Tian, Y.; Mao-Ying, Q.L.; Jiang, J.W.; Ma, H.J.; et al. Aspirin-Triggered Lipoxin A4 Attenuates Mechanical Allodynia in Association with Inhibiting Spinal JAK2/STAT3 Signaling in Neuropathic Pain in Rats. Neuroscience 2014, 273, 65–78. [CrossRef]eng
dcterms.referencesSun, T.; Yu, E.; Yu, L.; Luo, J.; Li, H.; Fu, Z. LipoxinA(4) Induced Antinociception and Decreased Expression of NF-KB and pro-Inflammatory Cytokines after Chronic Dorsal Root Ganglia Compression in Rats. Eur. J. Pain 2012, 16, 18–27. [CrossRef]eng
dcterms.referencesTian, Y.; Liu, M.; Mao-Ying, Q.-L.; Liu, H.; Wang, Z.-F.; Zhang, M.-T.; Wang, J.; Li, Q.; Liu, S.-B.; Mi, W.-L.; et al. Early Single Aspirin-Triggered Lipoxin Blocked Morphine Anti-Nociception Tolerance through Inhibiting NALP1 Inflammasome: Involvement of PI3k/Akt Signaling Pathway. Brain Behav. Immun. 2015, 50, 63–77. [CrossRef]eng
dcterms.referencesHuang, L.; Wang, C.-F.; Serhan, C.N.; Strichartz, G. Enduring Prevention and Transient Reduction of Postoperative Pain by Intrathecal Resolvin D1. Pain 2011, 152, 557–565. [CrossRef] [PubMed]eng
dcterms.references. Liu, Z.; Miao, G.; Wang, J.; Yang, C.; Fu, Z.; Sun, T. Resolvin D1 Inhibits Mechanical Hypersensitivity in Sciatica by Modulating the Expression of Nuclear Factor-KB, Phospho-Extracellular Signal-Regulated Kinase, and Pro- and Antiinflammatory Cytokines in the Spinal Cord and Dorsal Root Ganglion. Anesthesiology 2016, 124, 934–944. [CrossRef]eng
dcterms.referencesZhang, L.; Terrando, N.; Xu, Z.-Z.; Bang, S.; Jordt, S.-E.; Maixner, W.; Serhan, C.N.; Ji, R.-R. Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-Operative Pain after Bone Fracture in Mice. Front. Pharmacol. 2018, 9, 412. [CrossRef]eng
dcterms.referencesKlein, C.P.; Sperotto, N.D.M.; Maciel, I.S.; Leite, C.E.; Souza, A.H.; Campos, M.M. Effects of D-Series Resolvins on Behavioral and Neurochemical Changes in a Fibromyalgia-like Model in Mice. Neuropharmacology 2014, 86, 57–66. [CrossRef] [PubMed]eng
dcterms.referencesFonseca, F.C.; Orlando, R.M.; Turchetti-Maia, R.M.; de Francischi, J.N. Comparative Effects of the Ω3 Polyunsaturated Fatty Acid Derivatives Resolvins E1 and D1 and Protectin DX in Models of Inflammation and Pain. J. Inflamm. Res. 2017, 10, 119–133. [CrossRef]eng
dcterms.referencesBarden, A.; Mas, E.; Croft, K.D.; Phillips, M.; Mori, T.A. Short-Term n-3 Fatty Acid Supplementation but Not Aspirin Increases Plasma Proresolving Mediators of Inflammation. J. Lipid Res. 2014, 55, 2401–2407. [CrossRef]eng
dcterms.referencesTjonahen, E.; Oh, S.F.; Siegelman, J.; Elangovan, S.; Percarpio, K.B.; Hong, S.; Arita, M.; Serhan, C.N. Resolvin E2: Identification and Anti-Inflammatory Actions: Pivotal Role of Human 5-Lipoxygenase in Resolvin E Series Biosynthesis. Chem. Biol. 2006, 13, 1193–1202. [CrossRef] [PubMed]eng
dcterms.referencesIsobe, Y.; Arita, M.; Iwamoto, R.; Urabe, D.; Todoroki, H.; Masuda, K.; Inoue, M.; Arai, H. Stereochemical Assignment and Anti-Inflammatory Properties of the Omega-3 Lipid Mediator Resolvin E3. J. Biochem. 2013, 153, 355–360. [CrossRef] [PubMed]eng
dcterms.referencesA.T. Resolve SARL. A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery. 2019. Available online: clinicaltrials.gov (accessed on 10 July 2021).eng
dcterms.referencesRamsden, C.E.; Faurot, K.R.; Zamora, D.; Palsson, O.S.; MacIntosh, B.A.; Gaylord, S.; Taha, A.Y.; Rapoport, S.I.; Hibbeln, J.R.; Davis, J.M.; et al. Targeted Alterations in Dietary N-3 and n-6 Fatty Acids Improve Life Functioning and Reduce Psychological Distress among Patients with Chronic Headache: A Secondary Analysis of a Randomized Trial. Pain 2015, 156, 587–596. [CrossRef]eng
dcterms.referencesTajmirriahi, M.; Sohelipour, M.; Basiri, K.; Shaygannejad, V.; Ghorbani, A.; Saadatnia, M. The Effects of Sodium Valproate with Fish Oil Supplementation or Alone in Migraine Prevention: A Randomized Single-Blind Clinical Trial. Iran. J. Neurol. 2012, 11, 21–24.eng
dcterms.referencesCaturla, N.; Funes, L.; Pérez-Fons, L.; Micol, V. A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of a Combination of Lemon Verbena Extract and Fish Oil Omega-3 Fatty Acid on Joint Management. J. Altern. Complement. Med. 2011, 17, 1051–1063. [CrossRef]eng
dcterms.referencesTomer, A.; Kasey, S.; Connor, W.E.; Clark, S.; Harker, L.A.; Eckman, J.R. Reduction of Pain Episodes and Prothrombotic Activity in Sickle Cell Disease by Dietary N-3 Fatty Acids. Thromb. Haemost. 2001, 85, 966–974. [CrossRef]eng
dcterms.referencesDurán, A.M.; Salto, L.M.; Câmara, J.; Basu, A.; Paquien, I.; Beeson, W.L.; Firek, A.; Cordero-MacIntyre, Z.; De León, M. Effects of Omega-3 Polyunsaturated Fatty-Acid Supplementation on Neuropathic Pain Symptoms and Sphingosine Levels in Mexican-Americans with Type 2 Diabetes. Diabetes Metab. Syndr. Obes. Targets Ther. 2019, 12, 109–120. [CrossRef]eng
dcterms.referencesBarden, A.E.; Moghaddami, M.; Mas, E.; Phillips, M.; Cleland, L.G.; Mori, T.A. Specialised Pro-Resolving Mediators of Inflammation in Inflammatory Arthritis. Prostaglandins Leukot. Essent. Fatty Acids 2016, 107, 24–29. [CrossRef]eng
dcterms.referencesKremer, J.M.; Lawrence, D.A.; Jubiz, W.; DiGiacomo, R.; Rynes, R.; Bartholomew, L.E.; Sherman, M. Dietary Fish Oil and Olive Oil Supplementation in Patients with Rheumatoid Arthritis. Clinical and Immunologic Effects. Arthritis Rheum. Off. J. Am. Coll. Rheumatol. 1990, 33, 810–820. [CrossRef] [PubMed]eng
dcterms.referencesGeusens, P.; Wouters, C.; Nijs, J.; Jiang, Y.; Dequeker, J. Long-Term Effect of Omega-3 Fatty Acid Supplementation in Active Rheumatoid Arthritis. A 12-Month, Double-Blind, Controlled Study. Arthritis Rheum. Off. J. Am. Coll. Rheumatol. 1994, 37, 824–829. [CrossRef] [PubMed]eng
dcterms.referencesTulleken, J.E.; Limburg, P.C.; Muskiet, F.A.; van Rijswijk, M.H. Vitamin E Status during Dietary Fish Oil Supplementation in Rheumatoid Arthritis. Arthritis Rheum. Off. J. Am. Coll. Rheumatol. 1990, 33, 1416–1419. [CrossRef] [PubMed]eng
dcterms.referencesGalarraga, B.; Khan, F.; Kumar, P.; Pullar, T.; Belch, J.J.F. C-Reactive Protein: The Underlying Cause of Microvascular Dysfunction in Rheumatoid Arthritis. Rheumatology 2008, 47, 1780–1784. [CrossRef] [PubMed]eng
dcterms.referencesLamon-Fava, S.; So, J.; Mischoulon, D.; Ziegler, T.R.; Dunlop, B.W.; Kinkead, B.; Schettler, P.J.; Nierenberg, A.A.; Felger, J.C.; Maddipati, K.R.; et al. Dose- and Time-Dependent Increase in Circulating Anti-Inflammatory and pro-Resolving Lipid Mediators Following Eicosapentaenoic Acid Supplementation in Patients with Major Depressive Disorder and Chronic Inflammation. Prostaglandins Leukot. Essent. Fatty Acids 2021, 164, 102219. [CrossRef] [PubMed]eng
dcterms.referencesAbdelhalim, S.M.N.S. Comparative Effectiveness of the Different Treatment Modalities for Management of Vaso-Occlusive Painful Crisis in Pediatric Sickle Cell Disease. 2021. Available online: clinicaltrials.gov (accessed on 10 July 2021).eng
dcterms.referencesKenney, K. Targeted Alteration in Omega-3 and Omega-6 Fatty Acids for Post-Traumatic Headache (Nutrition for PTH). 2018. Available online: clinicaltrials.gov (accessed on 10 July 2021)eng
dcterms.referencesUniversidade do Porto. Effects of an Anti-Inflammatory Nutritional Intervention in Disease Assessment Parameters, Inflammatory Markers, and Quality of Life of Patients with Fibromyalgia. 2020. Available online: clinicaltrials.gov (accessed on 10 July 2021).eng
dcterms.referencesCostenbader, K.H. Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain. 2021. Available online: clinicaltrials.gov (accessed on 10 July 2021)eng
dcterms.referencesUniversity of North Carolina. Chapel Hill Pilot, Double-Blind, Randomized Controlled, Multi-Center Study of the Effects of Fish Oil and Vitamin D in the Prevention of Chronic Pain Following Major Thermal Burn Injury. 2020. Available online: clinicaltrials.gov (accessed on 10 July 2021)eng
dcterms.referencesSwisse Wellness Pty Ltd. A Randomised, Double-Blind, Placebo Controlled Study to Investigate the Effect on Knee Pain Reduction and Safety of Swisse High Strength Deep Sea Krill Oil (Superba BOOST) in Adults with Mild to Moderate Osteoarthritis of the Knee. 2020. Available online: clinicaltrials.gov (accessed on 10 July 2021).eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
2021_MDPI_Specialized_Pro-Resolving_Lipid_Mediators.pdf
Tamaño:
1.07 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca